Patents by Inventor Peter M. Clark
Peter M. Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11920538Abstract: An anti-polish ring for an internal combustion engine is provided. The anti-polish ring includes an axially extending ring portion that is configured to scrape a top portion of a piston in a cylinder liner. The anti-polish ring is configured to accommodate passage of an intake or exhaust valve thereby. The anti-polish ring may include an alignment feature so that the anti-polish ring is inserted in a predetermined orientation in the cylinder. The anti-polish ring may include a heat shield and/or a seating member.Type: GrantFiled: November 3, 2022Date of Patent: March 5, 2024Assignee: Cummins Inc.Inventors: Owen Summerfield, Craig Daniel Fox, Robert Harries, Jamie Kehoe, Kent H. Clark, John M Antonevich, Reid M. Irish, Scott A. Ragon, Stephen G. Townsend, Peter Thomas Quanz
-
Publication number: 20240058340Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.Type: ApplicationFiled: September 20, 2021Publication date: February 22, 2024Inventors: Jean-Michel Vernier, David A. Nathanson, Michael E. Jung, Timothy F. Cloughesy, Lorenz Urner, Peter M. Clark, Jonathan Tsang
-
Publication number: 20240043390Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.Type: ApplicationFiled: May 22, 2023Publication date: February 8, 2024Inventors: David A. Nathanson, Wilson X. Mai, Michael E. Jung, Peter M. Clark, Timothy F. Cloughesy, Gyudong Kim, Johathan Tsang, Lorenz Urner
-
Publication number: 20230364091Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.Type: ApplicationFiled: September 20, 2021Publication date: November 16, 2023Inventors: David A. Nathanson, Michael E. Jung, Timothy F. Cloughesy, Lorenz Urner, Peter M. Clark, Jonathan Tsang
-
Publication number: 20230115366Abstract: The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.Type: ApplicationFiled: June 29, 2022Publication date: April 13, 2023Inventors: David A. Nathanson, Michael E. Jung, Jonathan Tsang, Lorenz Urner, Peter M. Clark, Timothy F. Cloughesy, Gyudong Kim
-
Patent number: 11377451Abstract: The present disclosure relates to compounds, compositions and methods for treating cancer, including compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating cancer in the brain, including glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating cancers such as glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.Type: GrantFiled: September 14, 2021Date of Patent: July 5, 2022Assignee: The Regents of the University of CaliforniaInventors: David A. Nathanson, Michael E. Jung, Jonathan Tsang, Lorenz Urner, Peter M. Clark, Timothy F. Cloughesy, Gyudong Kim
-
Publication number: 20220064177Abstract: The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.Type: ApplicationFiled: September 14, 2021Publication date: March 3, 2022Inventors: David A. Nathanson, Michael E. Jung, Jonathan Tsang, Lorenz Urner, Peter M. Clark, Timothy F. Cloughesy, Gyudong Kim
-
Publication number: 20200290978Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.Type: ApplicationFiled: September 26, 2018Publication date: September 17, 2020Applicant: The Regents of the University of CaliforniaInventors: David A. Nathanson, Wilson X. Mai, Michael E. Jung, Peter M. Clark, Timothy F. Cloughesy, Gyudong Kim, Jonathan Tsang, Lorenz Urner
-
Patent number: 9592309Abstract: The invention disclosed herein discloses selected ribose isomers that are useful as PET probes (e.g. [18F]-2-fluoro-2-deoxy-arabinose). These PET probes are useful, for example, in methods designed to monitor physiological processes including ribose metabolism and/or to selectively observe certain tissue/organs in vivo. The invention disclosed herein further provides methods for making and using such probes.Type: GrantFiled: May 9, 2013Date of Patent: March 14, 2017Assignee: The Regents of the University of CaliforniaInventors: Owen Witte, Peter M. Clark, Blanca Graciela Flores Castillo, Michael E. Jung, Nikolai M. Evdokimov
-
Publication number: 20160282359Abstract: An apparatus and method for detecting an analyte are described. The apparatus includes at least one microchannel adapted for an analyte to adhere to an interior surface thereof, a mixing element positioned within at least a portion of the at least one microchannel, a light source for energizing quantum dots conjugated with the analyte within the at least one microchannel, and a detection system for detecting and quantifying fluorescent energy emitted by the quantum dots in one or more predetermined wavelength ranges, wherein each wavelength range being correlated to one and only one type of analyte.Type: ApplicationFiled: June 2, 2016Publication date: September 29, 2016Applicant: Drexel UniversityInventors: Elisabeth Papazoglou, Hongseok Noh, Chengjie Yu, Peter M. Clark
-
Patent number: 9134308Abstract: Provided is a method for immobilizing a macromolecule to a solid support material using poly(ethylene glycol), and a device obtained from the method. The macromolecule can be a polypeptide, such as an antibody.Type: GrantFiled: May 12, 2011Date of Patent: September 15, 2015Assignee: Drexel UniversityInventors: David R. Hansberry, Peter M. Clark, Elisabeth Papazoglou, Sundar Babu Nadarajan, Constantinos Papathomas
-
Publication number: 20150133777Abstract: The invention disclosed herein discloses selected ribose isomers that are useful as PET probes (e.g. [18F]-2-fluoro-2-deoxy-arabinose). These PET probes are useful, for example, in methods designed to monitor physiological processes including ribose metabolism and/or to selectively observe certain tissue/organs in vivo. The invention disclosed herein further provides methods for making and using such probes.Type: ApplicationFiled: May 9, 2013Publication date: May 14, 2015Inventors: Owen Witte, Peter M. Clark, Blanca Graciela Flores Castillo, Michael E. Jung, Nikolai M. Evdokimov
-
Publication number: 20140093979Abstract: An apparatus and method for detecting an analyte are described. The apparatus includes at least one microchannel adapted for an analyte to adhere to an interior surface thereof, a mixing element positioned within at least a portion of the at least one microchannel, a light source for energizing quantum dots conjugated with the analyte within the at least one microchannel, and a detection system for detecting and quantifying fluorescent energy emitted by the quantum dots in one or more predetermined wavelength ranges, wherein each wavelength range being correlated to one and only one type of analyte.Type: ApplicationFiled: October 1, 2013Publication date: April 3, 2014Applicant: Drexel UniversityInventors: Elisabeth Papazoglou, Hongseok Noh, Chengjie Yu, Peter M. Clark
-
Publication number: 20130178587Abstract: Provided is a method for immobilizing a macromolecule to a solid support material using poly(ethylene glycol), and a device obtained from the method. The macromolecule can be a polypeptide, such as an antibody.Type: ApplicationFiled: May 12, 2011Publication date: July 11, 2013Applicant: Drexel UniversityInventors: David R. Hansberry, Peter M. Clark, Sundar Babu Nadarajan, Constantinos Papathomas
-
Publication number: 20120009387Abstract: A biodegradable, polyolefin-based material composition having incorporated therein thermoplastic starch particles is described. The material includes from about 5% to about 45% of a thermoplastic starch (TPS), from about 55% to about 95% of a polyolefin or mixtures of polyolefins, and from about 0.5% to about 8% of a compatibilizer, which has a non-polar backbone and a polar functional monomer or a block copolymer of both the non-polar block and a polar block. A method of forming a film and packaging assemblies made with the polymeric material are also described.Type: ApplicationFiled: August 17, 2011Publication date: January 12, 2012Inventors: James H. Wang, Peter M. Clark, Yiwu Guan, Yan Wang, Xueen George Hao, Tong-tong Zhang